Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On August2, 2017, Dynavax Technologies Corporation (“Dynavax”) issued a press release announcing its financial results for the quarter ended June30, 2017. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
The information with respect to Item 2.02 in this current report and its accompanying exhibit shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
| Item 2.02. | Financial Statements and Exhibits |
(d) Exhibits. The following exhibit is furnished herewith:
| 99.1 | Press Release, dated August2, 2017, titled “Dynavax Reports Second Quarter 2017 Financial Results” |
DYNAVAX TECHNOLOGIES CORP ExhibitEX-99.1 2 d403161dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 DYNAVAX REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS BERKELEY,…To view the full exhibit click here
About Dynavax Technologies Corporation (NASDAQ:DVAX)
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
